Mead, Richard J. http://orcid.org/0000-0002-3207-0068
Shan, Ning
Reiser, H. Joseph http://orcid.org/0000-0001-5728-2879
Marshall, Fiona http://orcid.org/0000-0002-8681-005X
Shaw, Pamela J. http://orcid.org/0000-0002-8925-2567
Article History
Accepted: 11 November 2022
First Online: 21 December 2022
Competing interests
: R.J.M. is cofounder of and holds shares in Keapstone Therapeutics, collaborates and receives funding from BenevolentAI, Quell Therapeutics, Sosei Heptares and MSD, is a consultant to Aclipse Therapeutics, has shares in Aclipse One Inc and is an inventor on patents related to M102. N.S. is an employee and shareholder of Aclipse Therapeutics. H.J.R. is the chairman of the Board of Aclipse Therapeutics. F.M. is an employee and shareholder of Merck and Co. P.J.S. is an advisory board member and consultant for Biogen, Aclipse Therapeutics, Quell Therapeutics, BenevolentAI, QurAlis, Astex, GeniUS and Eli Lilly and collaborates with and receives research funding from Quell Therapeutics, Aclipse Therapeutics, Pfizer and SwanBio. She is a cofounder of and holds shares in Keapstone Therapeutics and holds shares in Aclipse One Inc. She is an inventor on patents related to low-dose IL-2, SRSF1 and M102. Support for clinical trials participation in the last five years has been received from Biogen, Alexion, Orion Pharma, WAVE, the EU Horizon 2020 programme and UK NIHR.
Free to read: This content has been made available to all.